Lat­est news on Covid boost­ers safe­ty sig­nal; As­traZeneca leads trio of M&A; The biggest news out of #JPM23; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Hel­lo — we know it’s not Sat­ur­day but Mon­day, but since End­points News is tak­ing a break for MLK Day, we thought we’d change up the time this week. Whether you’re re­cov­er­ing from the JP Mor­gan con­fer­ence like me or watched from afar, this edi­tion of the End­points Week­ly has got you cov­ered on every­thing you need to know from last week. I was thrilled to meet some of you in San Fran­cis­co and learned so much from con­ver­sa­tions, for­mal or in­for­mal. It’s been more than three years since I’ve stepped foot in the US (or left Asia!), so the trip was ex­tra spe­cial.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER